Shunho Terminates HNB Plans Due to Policy Changes

Feb.08.2025
Shunho Terminates HNB Plans Due to Policy Changes
Investors question Shunho's progress on HNB manufacturing project; company terminates plans due to policy changes.

Recently, investors inquired on the investor interaction platform about Shunho Corporation (002565.SZ) and whether the company's previously planned "project to manufacture 200 million HNB wake-up sticks per year" is still progressing. If it has been terminated, they also asked if there are any similar new tobacco expansion plans.


In response, Shunho Corporation stated that due to adjustments in national policies, the construction of the project was difficult to proceed with. After the expiration of the project agreement, the company has reached a consensus with the relevant parties and signed the "Cancellation Agreement for the construction of the Green Electronic HNB Stick Manufacturing Project with an annual capacity of 200 million units". For further details, please refer to the announcement released by the company on August 17, 2024 (announcement number: 2024-050). Regarding the company's strategic planning in the new tobacco field, investors are advised to refer to the periodic reports that have been published.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China National Tobacco Corp paid $222 bln into state finances in 2025
China National Tobacco Corp paid $222 bln into state finances in 2025
China National Tobacco Corporation (CNTC) paid a record $222 billion into China’s state finances in 2025, according to official industry data.
Special Report
Jan.23
USITC Launches Section 337 Probe Into Disposable and Closed-System ENDS, Involving 16 Companies
USITC Launches Section 337 Probe Into Disposable and Closed-System ENDS, Involving 16 Companies
The U.S. International Trade Commission (USITC) voted to institute a Section 337 investigation into certain disposable and other closed-system electronic nicotine delivery systems (ENDS) devices and components thereof (Inv. No. 337-TA-1486). The investigation stems from a complaint filed on January 13, 2026 by R.J. Reynolds entities based in Winston-Salem, North Carolina, supplemented on February 3, 2026.
Mar.05 by 2FIRSTS.ai
Canada: “I Want My Pouches” launches during National Non-Smoking Week to push easier adult access to nicotine pouches
Canada: “I Want My Pouches” launches during National Non-Smoking Week to push easier adult access to nicotine pouches
Canadian consumer advocacy group I Want My Pouches announced its launch during National Non-Smoking Week, calling for straightforward, consistent and practical adult access to nicotine pouches.
Jan.22 by 2FIRSTS.ai
JTI UK Updates Nordic Spirit Packaging to Strengthen “Strength and Flavour” Guidance
JTI UK Updates Nordic Spirit Packaging to Strengthen “Strength and Flavour” Guidance
Japan Tobacco International UK (JTI UK) has unveiled a refreshed brand identity for Nordic Spirit nicotine pouches. The new packaging is now live on JTI360 and will roll out to shelves over the coming months. The updated design strengthens on-pack guidance on strength and flavour, adding slower/faster release cues and a six-dot strength system (6–17mg). Each can contains 20 pouches and includes a lid compartment for storing used pouches before disposal.
Mar.04 by 2FIRSTS.ai
Product | Detachable Battery + Dual-Battery System: RAZ VUE 50K Launches on U.S. Online Vape Channels
Product | Detachable Battery + Dual-Battery System: RAZ VUE 50K Launches on U.S. Online Vape Channels
RAZ has recently launched the RAZ VUE 50K on U.S. online vape channels, positioning it as the brand’s first disposable vape featuring a detachable battery. The device uses a dual-battery setup—an integrated 420mAh battery in the pod paired with a reusable 900mAh power bank—and is rated for up to approximately 50,000 puffs in Normal Mode.
Jan.16 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11